摘要
目的观察经导管肝动脉化疗栓塞+射频消融(TACE+RAF)微创治疗联合CIK细胞对肝癌的疗效及毒副反应。方法根据纳入标准,共收集41例,随机分为2组,治疗组(TACE/RAF+CIK)20例,对照组(TACE/RAF)21例。评价两组的副反应、AFP的变化和生存率的差异。结果应用CIK治疗未发现明显不良反应;CIK治疗后,在9个月内,患者AFP水平较对照组低,9个月后无统计学差异;无瘤生存率及1年生存率,治疗组优于对照组,3年生存率无明显差异。结论 CIK细胞治疗副作用小,可提高患者1年生存率,降低肿瘤的复发和转移。
Objective To observe the efficacy and toxicity of reaction of the minimally invasive treatment （TACE ＋ RAF） combined with CIK cells for liver cancer. Method Based on the inclusion criteria, 41 cases were collected and randomly divided into 2 groups, 20 patients in treatment group （TACE/RAF＋CIK） and 21 cases in the control group （TACE/RAF）. Side effects, the AFP of change and survival differences were evaluated. Results No significant adverse reactions were found and patients with AFP level was lower in treatment group than the control group. Tumor-free survival and 1-year survival rate is well in the treatment group than the control group, and no significant difference in the 3-year survival rates between these groups. Conclusion CIK cell therapy is safe, can improve the 1-year survival rate of patients and reduce tumor recurrence and metastasis.
出处
《岭南现代临床外科》
2013年第1期29-31,共3页
Lingnan Modern Clinics in Surgery
基金
广东省科技计划项目(2010B060900088)
关键词
CIK细胞
免疫治疗
肝癌
CIK cells
Immunotherapy
Hepatocellular carcinoma
